Stokes Family Office LLC Purchases Shares of 4,484 Novartis AG (NYSE:NVS)

Stokes Family Office LLC purchased a new stake in shares of Novartis AG (NYSE:NVS) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 4,484 shares of the company’s stock, valued at approximately $436,000.

Several other institutional investors have also added to or reduced their stakes in NVS. Foundations Investment Advisors LLC boosted its holdings in shares of Novartis by 26.9% in the 4th quarter. Foundations Investment Advisors LLC now owns 89,074 shares of the company’s stock worth $8,668,000 after purchasing an additional 18,894 shares during the period. CWA Asset Management Group LLC boosted its holdings in shares of Novartis by 20.1% in the 4th quarter. CWA Asset Management Group LLC now owns 30,840 shares of the company’s stock worth $3,001,000 after purchasing an additional 5,164 shares during the period. Quantbot Technologies LP boosted its holdings in shares of Novartis by 135.5% in the 3rd quarter. Quantbot Technologies LP now owns 39,976 shares of the company’s stock worth $4,598,000 after purchasing an additional 22,998 shares during the period. Chicago Partners Investment Group LLC purchased a new position in shares of Novartis in the 4th quarter worth approximately $239,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Novartis by 13.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 157,256 shares of the company’s stock worth $18,088,000 after acquiring an additional 18,990 shares during the last quarter. Hedge funds and other institutional investors own 13.12% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on NVS. Deutsche Bank Aktiengesellschaft raised Novartis from a “hold” rating to a “buy” rating in a research note on Tuesday, February 4th. Barclays reissued an “underweight” rating on shares of Novartis in a research note on Monday, February 3rd. HSBC lowered Novartis from a “hold” rating to a “reduce” rating in a research note on Wednesday, December 4th. StockNews.com raised Novartis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 8th. Finally, Morgan Stanley assumed coverage on Novartis in a research note on Wednesday, February 12th. They set an “underweight” rating for the company. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Novartis currently has a consensus rating of “Hold” and a consensus price target of $123.38.

Novartis Trading Down 0.6 %

Shares of NYSE NVS opened at $111.51 on Thursday. The company has a quick ratio of 0.84, a current ratio of 1.04 and a debt-to-equity ratio of 0.48. The business has a fifty day simple moving average of $106.14 and a two-hundred day simple moving average of $107.50. The firm has a market cap of $227.92 billion, a PE ratio of 18.96, a price-to-earnings-growth ratio of 1.70 and a beta of 0.53. Novartis AG has a twelve month low of $92.35 and a twelve month high of $120.92.

Novartis (NYSE:NVS) last released its quarterly earnings results on Friday, January 31st. The company reported $1.98 EPS for the quarter, topping the consensus estimate of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. Analysts expect that Novartis AG will post 8.45 earnings per share for the current fiscal year.

Novartis Announces Dividend

The business also recently declared a dividend, which was paid on Wednesday, March 12th. Stockholders of record on Wednesday, March 12th were given a $3.8695 dividend. The ex-dividend date of this dividend was Wednesday, March 12th. Novartis’s payout ratio is 42.69%.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.